Keywords
triple-negative breast cancer
prognosis
Kinshasa
immunohistochemistry
How to Cite
Abstract
Introduction
Triple-negative breast cancer (TNBC), known for its particularly aggressive nature, is associated with a poor prognosis. Tumour-infiltrating lymphocytes (TILs) are emerging as a key prognostic biomarker in this subtype.
Purpose
To quantitatively analyse TILs and explore their association with clinical and pathological characteristics among Congolese patients.
Methods
A cross-sectional, descriptive study was conducted between January 2022 and December 2024 in two reference cytopathology laboratories in Kinshasa (University Clinics and LEBOMA Pathology Cabinet). A convenience sample of 147 breast cancer patients was included, of whom 28 had triple-negative breast cancer confirmed by immunohistochemistry. Data were extracted using Microsoft Excel 2016 and analysed with SPSS version 27. Proportion comparisons were performed using the chi-square test, with statistical significance set at p < 0.05.
Results
Among the 147 breast cancer patients included, 28 (19.05%) had TNBC. The intermediate TIL group was the most represented (39.3%), predominantly associated with grade 3 tumours, followed by the low TIL group (35%), where grade 2 tumours predominated (60%). The age group ≤ 50 years accounted for 19 patients (67.9%), among whom 9 (47.3%; 95% CI [27.3–68.3]) had intermediate TILs. A low degree of TILs was observed in 6 patients (66.7%) aged > 50 years. A Ki-67 proliferative index > 30% was noted in 21 patients (75%), of whom 10 (47.6%; 95% CI [28.3–67.6]) had intermediate TILs.
Conclusion
The majority of TNBC patients had TIL levels ≥10. High TIL density was associated with younger age and a lower Ki-67 proliferation index. TIL assessment therefore emerges as a relevant prognostic biomarker that could guide patient follow-up and therapeutic decision-making, particularly regarding immunotherapy.
References
Amasa, P. J. I., Azama, M. S., Tshofu, E. D., Okitokonda, F. D., Lenga, S. L., Kalunda, É. P., & Loshima, E. O. (2024). Results of breast cancer knowledge among Congolese women in Kinshasa: A cross-sectional study. PAMJ Clinical Medicine, 14(13). https://doi.org/10.11604/pamj-cm.2024.14.13.41634
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229–263. https://doi.org/10.3322/caac.21834
Bray, F., Parkin, D. M., & African Cancer Registry Network. (2022). Cancer in sub-Saharan Africa in 2020: A review of current estimates of the national burden, data gaps, and future needs. The Lancet Oncology, 23(6), 719–728. https://doi.org/10.1016/S1470-2045(22)00270-4
Campedel, L., Blanc-Durand, P., Bin Asker, A., Lehmann-Che, J., Cuvier, C., De Bazelaire, C., … Cottu, P. (2020). Prognostic impact of stromal immune infiltration before and after neoadjuvant chemotherapy (NAC) in triple negative inflammatory breast cancers (TNIBC) treated with dose-dense dose-intense NAC. Cancers, 12(9), 2657. https://doi.org/10.3390/cancers12092657
De Jong, V. M. T., Wang, Y., Ter Hoeve, N. D., Opdam, M., Stathonikos, N., Jóźwiak, K., … van Diest, P. J. (2022). Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. Journal of Clinical Oncology, 40(21), 2361–2374. https://doi.org/10.1200/JCO.21.01536
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., … Loibl, S. (2018). Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. The Lancet Oncology, 19(1), 40–50. https://doi.org/10.1016/S1470-2045(17)30904-X
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., … Jemal, A. (2019). Breast cancer statistics, 2019. CA: A Cancer Journal for Clinicians, 69(6), 438–451. https://doi.org/10.3322/caac.21583
Feng, J., Li, J., Huang, X., Yi, J., Wu, H., Zou, X., … Xie, X. (2021). Nomogram to predict tumor-infiltrating lymphocytes in breast cancer patients. Frontiers in Molecular Biosciences, 8, 761163. https://doi.org/10.3389/fmolb.2021.761163
Giaquinto, A. N., Sung, H., Newman, L. A., Freedman, R. A., Smith, R. A., Star, J., … Siegel, R. L. (2024). Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians, 74(6), 477–495. https://doi.org/10.3322/caac.21863
Gnangnon, F. (2024). Contribution à la connaissance du fardeau et des facteurs pronostiques du cancer du sein au Bénin et en Afrique au Sud du Sahara [Doctoral thesis, Université de Limoges & Université d’Abomey-Calavi]. HAL. https://theses.hal.science/tel-04921380
Goronzy, J. J., & Weyand, C. M. (2009). The ageing immune system. Nature Reviews Immunology, 9(12), 850–860. https://doi.org/10.1038/nri2674
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Inflammation and cancer: An ancient link with new paradigms. Cell, 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.038
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., … Piccart, M. (2014). Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Annals of Oncology, 25(8), 1544–1550. https://doi.org/10.1093/annonc/mdu112
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., … von Minckwitz, G. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of Oncology, 33(11), 1149–1158. https://doi.org/10.1016/j.annonc.2022.07.1940
Maseb’a Mwang Sulu, S., Batalansi, D. B., Sulu, A. M. S., Mukuku, O., Mboloko, J. E., Mashinda, D. K., … Tshibassu, P. M. (2022). Immunohistochemical features of breast cancer seen in women in Kinshasa, Democratic Republic of the Congo: A six-year retrospective study. International Journal of Breast Cancer, 2022, 8860947. https://doi.org/10.1155/2022/8860947
Mashinda, D. K., Kayembe, K., & Mapatano, M. (2012, June 27). Cancer prevalence in the Democratic Republic of the Congo: Anatomopathologic data collected at the Cliniques Universitaires and Hôpital Général de Référence de Kinshasa. Annales africaines de médecine. https://anafrimed.net/prevalence-du-cancer-en-republique-democratique-du-congo
Natacha, J., Kordahi, M., Blanc-Fournier, C., & Lacroix-Triki, M. (n.d.). Assessment of tumor-infiltrating lymphocytes in breast cancers: How to apply international recommendations 2014. EM-Consulte. Retrieved July 16, 2025, from https://www.em-consulte.com/article/1104396/evaluation-des-lymphocytes-infiltrant-la-tumeur
Ngwala, P. L., Ngangu, P. N., Diakengua, V., Kalombo, C., Nyambu, J., Landu, J., … Kayembe, P. (n.d.). Epidemiology of cancer in rural Congo: Case of IME Kimpese Hospital, Democratic Republic of Congo. Open Journal of Epidemiology. https://www.scirp.org/journal/paperinformation?paperid=107856
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., ... Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Annals of Oncology, 26(2), 259–271. https://doi.org/10.1093/annonc/mdu450
Santhanam, R., Bains, S. L., An, M., & Al-Hajj, M. (2018). Age-related changes in the tumour microenvironment and their impact on tumour immunity. Journal of Hematology & Oncology, 11(1), 108. https://doi.org/10.1186/s13045-018-0648-z
Takada, K., Kashiwagi, S., Asano, Y., Goto, W., Morisaki, T., Shibutani, M., … Hirakawa, K. (2022). Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age. World Journal of Surgical Oncology, 20(1), 38. https://doi.org/10.1186/s12957-022-02513-5
Wang, Y., Zong, B., Yu, Y., Wang, Y., Tang, Z., Chen, R., … Zhang, Y. (2021). Ki67 index changes and tumor-infiltrating lymphocyte levels impact the prognosis of triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Frontiers in Oncology, 11, 668610. https://doi.org/10.3389/fonc.2021.668610
World Health Organization. (n.d.). Breast cancer. Retrieved July 15, 2025, from https://www.who.int/news-room/fact-sheets/detail/breast-cancer
Zhu, X., Chen, L., Huang, B., Wang, Y., Ji, L., Wu, J., … Chen, X. (2020). The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Scientific Reports, 10(1), 225. https://doi.org/10.1038/s41598-019-57094-3
Authors of articles published in Orap J are the copyright holders of their articles. When they accept our terms of use, they grant any third party the right to use, reproduce or disseminate their article freely without fiscal or registration restrictions.